NASDAQ:CERE Cerevel Therapeutics (CERE) Stock Forecast, Price & News $33.66 +1.06 (+3.25%) (As of 02:33 PM ET) Add Compare Share Share Today's Range$32.36▼$33.7450-Day Range$23.90▼$34.0052-Week Range$22.10▼$41.46Volume213,761 shsAverage Volume579,686 shsMarket Capitalization$5.28 billionP/E RatioN/ADividend YieldN/APrice Target$34.80 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Cerevel Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside3.4% Upside$34.80 Price TargetShort InterestBearish6.99% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.08Based on 8 Articles This WeekInsider TradingSelling Shares$4.52 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.70) to ($2.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.23 out of 5 starsMedical Sector954th out of 981 stocksPharmaceutical Preparations Industry467th out of 481 stocks 2.3 Analyst's Opinion Consensus RatingCerevel Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 8 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.80, Cerevel Therapeutics has a forecasted upside of 3.4% from its current price of $33.66.Amount of Analyst CoverageCerevel Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.99% of the float of Cerevel Therapeutics has been sold short.Short Interest Ratio / Days to CoverCerevel Therapeutics has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Cerevel Therapeutics has recently increased by 5.83%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCerevel Therapeutics does not currently pay a dividend.Dividend GrowthCerevel Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CERE. Previous Next 2.3 News and Social Media Coverage News SentimentCerevel Therapeutics has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Cerevel Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for CERE on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.MarketBeat Follows2 people have added Cerevel Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cerevel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,518,940.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Cerevel Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cerevel Therapeutics are expected to decrease in the coming year, from ($2.70) to ($2.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerevel Therapeutics is -13.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerevel Therapeutics is -13.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerevel Therapeutics has a P/B Ratio of 10.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cerevel Therapeutics (NASDAQ:CERE) StockCerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.Read More Receive CERE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CERE Stock News HeadlinesJune 7, 2023 | americanbankingnews.comMark Bodenrader Sells 1,895 Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) StockJune 7, 2023 | americanbankingnews.comN Anthony Coles Sells 50,000 Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) StockJune 8, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. June 4, 2023 | seekingalpha.comCerevel: High Priced Stock Doing Interesting ScienceMay 24, 2023 | 247wallst.comGoldman Sachs Maintains Cerevel Therapeutics Neutral RecommendationMay 24, 2023 | msn.comGoldman Sachs Maintains Cerevel Therapeutics Holdings (CERE) Neutral RecommendationMay 23, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE) and Icecure Medical (ICCM)May 23, 2023 | americanbankingnews.comBrokerages Set Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Price Target at $34.80June 8, 2023 | Edge On The Street (Ad)New "Mined in America" Lithium Opportunities?The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.May 16, 2023 | markets.businessinsider.comMizuho Securities Sticks to Its Buy Rating for Athira Pharma (ATHA)May 16, 2023 | it.tmcnet.comGoogle Cloud Launches AI-powered Solutions to Safely Accelerate Drug Discovery and Precision MedicineMay 16, 2023 | msn.comGoogle Cloud launches A.I.-powered tools to accelerate drug discovery, precision medicineMay 12, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Astria Therapeutics (ATXS), Nkarta (NKTX)May 10, 2023 | markets.businessinsider.comCerevel Therapeutics Appoints Susan Altschuller As Its New CFOMay 10, 2023 | finance.yahoo.comCerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial OfficerMay 9, 2023 | msn.comMizuho Maintains Cerevel Therapeutics Holdings (CERE) Neutral RecommendationMay 9, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Cerevel Therapeutics Holdings, Inc. Lifted by Analyst (NASDAQ:CERE)May 8, 2023 | americanbankingnews.comMizuho Boosts Cerevel Therapeutics (NASDAQ:CERE) Price Target to $29.00May 7, 2023 | seekingalpha.comCerevel Therapeutics Holdings, Inc. 2023 Q1 - Results - Earnings Call PresentationMay 5, 2023 | msn.comWells Fargo Upgrades Cerevel Therapeutics Holdings (CERE)May 4, 2023 | americanbankingnews.comShort Interest in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Drops By 6.8%May 4, 2023 | americanbankingnews.comWells Fargo & Company Upgrades Cerevel Therapeutics (NASDAQ:CERE) to "Overweight"May 3, 2023 | seekingalpha.comCerevel Therapeutics GAAP EPS of -$0.67 in-lineMay 3, 2023 | markets.businessinsider.comMizuho Securities Keeps Their Hold Rating on Cerevel Therapeutics Holdings (CERE)May 3, 2023 | nasdaq.comCerevel Therapeutics Appoints Ron Renaud As CEO; Tony Coles To Remain ChairpersonMay 3, 2023 | markets.businessinsider.comCerevel Therapeutics Holdings Inc. Q1 loss increases in line with estimatesMay 3, 2023 | msn.comCerevel Therapeutics Hldg: Q1 Earnings InsightsSee More Headlines CERE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CERE Company Calendar Last Earnings5/03/2023Today6/08/2023Next Earnings (Estimated)8/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryCoal & Consumable Fuels SectorMedical Current SymbolNASDAQ:CERE CUSIP15677310 CIK767884 Webceres.net Phone844-304-2048FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Forecast$34.80 High Stock Price Forecast$46.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+6.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($2.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-351,510,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-77.15% Return on Assets-42.60% Debt Debt-to-Equity Ratio0.78 Current Ratio13.35 Quick Ratio13.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.33 per share Price / Book9.79Miscellaneous Outstanding Shares156,830,000Free Float148,835,000Market Cap$5.11 billion OptionableNot Optionable Beta1.47 Key ExecutivesDr. N. Anthony Coles Jr. (Age 62)M.P.H., Exec. Chairman & CEO Comp: $1.01MMr. Abraham N. Ceesay M.B.A. (Age 44)Pres Comp: $776.64kMr. Mark Bodenrader (Age 49)Interim CFO, VP of Fin. & Chief Accounting Officer Comp: $440.89kMr. Scott M. Akamine J.D. (Age 37)Chief Legal Officer & Corp. Sec. Comp: $444.74kDr. Ramiro Sanchez M.D. (Age 61)Chief Medical Officer Comp: $716.29kDr. John J. Renger Ph.D. (Age 53)Chief Scientific Officer Mr. Matthew CalistriVP of Investor RelationsMr. Kenneth A. DiPietro (Age 63)Chief HR Officer Ms. Kathleen Tregoning M.A. (Age 51)Chief Corp. Affairs Officer More ExecutivesKey CompetitorsOrganon & Co.NYSE:OGNAscendis Pharma A/SNASDAQ:ASNDAlkermesNASDAQ:ALKSMadrigal PharmaceuticalsNASDAQ:MDGLIVERIC bioNASDAQ:ISEEView All CompetitorsInsiders & InstitutionsMark BodenraderSold 1,895 sharesTotal: $62,440.25 ($32.95/share)N Anthony ColesSold 50,000 sharesTotal: $1.63 M ($32.60/share)New York State Common Retirement FundSold 10,684 shares on 5/18/2023Ownership: 0.019%JPMorgan Chase & Co.Bought 1,600 shares on 5/18/2023Ownership: 0.000%Jane Street Group LLCSold 14,300 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CERE Stock - Frequently Asked Questions Should I buy or sell Cerevel Therapeutics stock right now? 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last twelve months. There are currently 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CERE shares. View CERE analyst ratings or view top-rated stocks. What is Cerevel Therapeutics' stock price forecast for 2023? 12 equities research analysts have issued 1-year target prices for Cerevel Therapeutics' stock. Their CERE share price forecasts range from $22.00 to $46.00. On average, they predict the company's share price to reach $34.80 in the next twelve months. This suggests a possible upside of 6.7% from the stock's current price. View analysts price targets for CERE or view top-rated stocks among Wall Street analysts. How have CERE shares performed in 2023? Cerevel Therapeutics' stock was trading at $31.54 at the start of the year. Since then, CERE stock has increased by 3.4% and is now trading at $32.60. View the best growth stocks for 2023 here. Are investors shorting Cerevel Therapeutics? Cerevel Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 4,720,000 shares, an increase of 5.8% from the April 30th total of 4,460,000 shares. Based on an average trading volume of 666,600 shares, the short-interest ratio is currently 7.1 days. Approximately 7.0% of the company's stock are short sold. View Cerevel Therapeutics' Short Interest. When is Cerevel Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023. View our CERE earnings forecast. How were Cerevel Therapeutics' earnings last quarter? Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) posted its earnings results on Wednesday, May, 3rd. The biotechnology company reported ($0.67) EPS for the quarter, meeting analysts' consensus estimates of ($0.67). During the same quarter in the prior year, the business posted ($0.46) EPS. What ETFs hold Cerevel Therapeutics' stock? ETFs with the largest weight of Cerevel Therapeutics (NASDAQ:CERE) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), BlackRock Future Health ETF (BMED) and AI Powered Equity ETF (AIEQ). What other stocks do shareholders of Cerevel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), Alpha Natural Resources (ANRZQ), Cenveo (CVO), Hess (HES), Palatin Technologies (PTN), Aeterna Zentaris (AEZS) and Avid Bioservices (CDMO). What is Cerevel Therapeutics' stock symbol? Cerevel Therapeutics trades on the NASDAQ under the ticker symbol "CERE." Who are Cerevel Therapeutics' major shareholders? Cerevel Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.98%), Price T Rowe Associates Inc. MD (3.06%), BlackRock Inc. (2.86%), State Street Corp (2.00%), Federated Hermes Inc. (1.23%) and Geode Capital Management LLC (0.80%). Insiders that own company stock include Abraham Ceesay, Deval L Patrick, Gabrielle Sulzberger, John Renger, Mark Bodenrader, N Anthony Coles and Perceptive Advisors Llc. View institutional ownership trends. How do I buy shares of Cerevel Therapeutics? Shares of CERE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cerevel Therapeutics' stock price today? One share of CERE stock can currently be purchased for approximately $32.60. How much money does Cerevel Therapeutics make? Cerevel Therapeutics (NASDAQ:CERE) has a market capitalization of $5.11 billion. The biotechnology company earns $-351,510,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis. How many employees does Cerevel Therapeutics have? The company employs 200 workers across the globe. How can I contact Cerevel Therapeutics? Cerevel Therapeutics' mailing address is 1535 Rancho Conejo Blvd, THOUSAND OAKS, CA 91320-1440, United States. The official website for the company is ceres.net. The biotechnology company can be reached via phone at 844-304-2048 or via email at ir@cerevel.com. This page (NASDAQ:CERE) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerevel Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.